Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Donya Moradi Manesh"'
Autor:
Richard B. Lock, Malcolm A. Smith, Peter J. Houghton, Jean-Pierre Bourquin, Anthony Letai, Warren Kaplan, Catherine Billups, Raushan T. Kurmasheva, Donya Moradi Manesh, Luke Jones, Elise Tonna, Ingrid Boehm, Kathryn Evans, Barbara Szymanska, Mark J. Cowley, Beat Bornhauser, Laura High, Chintanu Sarmah, Viktoras Frismantas, Triona Ni Chonghaile, Hernan Carol, Santi Suryani
Supplementary Figures S6-S9. Correlations between BCL2 family gene expression and in vivo ABT-263 sensitivity in the MLL-ALL xenograft panel; S7. Correlations between BCL2 family gene expression and in vivo ABT-263 sensitivity in the BCP-ALL xenograf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15c22210571e10a4ce36db4d779b4d55
https://doi.org/10.1158/1078-0432.22454406
https://doi.org/10.1158/1078-0432.22454406
Publikováno v:
Expert Review of Clinical Immunology. 13:5-9
The discovery of clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (Cas9) and their subsequent development for gene modification has revolutionized ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1fec32f14bbaefaf009c4ea2700b5dd8
https://doi.org/10.1080/1744666x.2017.1241711
https://doi.org/10.1080/1744666x.2017.1241711
Autor:
Kathryn Evans, Raushan T. Kurmasheva, William R. Wilson, Donya Moradi Manesh, Ashlee Hedrick, Catherine A. Billups, Cara E. Toscan, Hernan Carol, Peter J. Houghton, Glenn M. Marshall, Jennifer Richmond, Rosemary Sutton, Lauryn S. Bracken, Jad El-Hoss, Malcolm A. Smith, Richard B. Lock
Publikováno v:
Blood. 126:1193-1202
PR-104, a phosphate ester of the nitrogen mustard prodrug PR-104A, has shown evidence of efficacy in adult leukemia clinical trials. Originally designed to target hypoxic cells, PR-104A is independently activated by aldo-keto-reductase 1C3 (AKR1C3).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::faefe87e0309154c0ba137f5e67fddf1
https://doi.org/10.1182/blood-2014-12-618900
https://doi.org/10.1182/blood-2014-12-618900
Autor:
Yongchuan Gu, William R. Wilson, Jad El-Hoss, Medhanie A. Mulaw, Karen L. MacKenzie, Marina Konopleva, Christopher P. Guise, Jeffrey Bruce Smaill, Adam V. Patterson, Stefan K. Bohlander, Juliana Benito, Susan M. Pullen, Donya Moradi Manesh, Stephen M. F. Jamieson, Duohui Jing, Annika Foehrenbacher, Richard B. Lock
Publikováno v:
Biochemical Pharmacology. 88:36-45
Aldo-keto reductase 1C3 (AKR1C3, EC 1.1.1.188) metabolises steroid hormones, prostaglandins and xenobiotics, and activates the dinitrobenzamide mustard prodrug PR-104A by reducing it to hydroxylamine PR-104H. Here, we describe a functional assay for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::799426a00ccb93d3e61b601f73542989
https://doi.org/10.1016/j.bcp.2013.12.019
https://doi.org/10.1016/j.bcp.2013.12.019
Autor:
Richard Gorlick, Hernan Carol, Richard B. Lock, Ian Hickson, Peter J. Houghton, Raushan T. Kurmasheva, Stephen T. Keir, John M. Maris, C. Patrick Reynolds, Min H. Kang, E. Anders Kolb, Malcolm A. Smith, Donya Moradi Manesh, Christopher L. Morton, Amy Wozniak, Dmitry Lyalin
Publikováno v:
Pediatric Blood & Cancer. 61:245-252
Background Quisinostat (JNJ-26481585) is a second-generation pyrimidyl-hydroxamic acid histone deacetylase (HDAC) inhibitor with high cellular potency towards Class I and II HDACs. Quisinostat was selected for clinical development as it showed prolon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::edcb9bf0385238c4f4398f4c122889b8
https://doi.org/10.1002/pbc.24724
https://doi.org/10.1002/pbc.24724
Autor:
Punam Malik, Donya Moradi Manesh
Publikováno v:
Gene Technology.
Genome editing using designer site-specific nucleases is a burgeoning field in which genomes of target cells/ organisms are now being manipulated to create/correct mutations or transcriptionally manipulate gene expression. The field began over a deca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::61e95cc30ab328fd077dd775b40b3d66
https://doi.org/10.4172/2329-6682.1000135
https://doi.org/10.4172/2329-6682.1000135
Autor:
Raushan T. Kurmasheva, Barbara Szymanska, Santi Suryani, Mark J. Cowley, Ingrid Boehm, Triona Ni Chonghaile, Warren Kaplan, Hernan Carol, Donya Moradi Manesh, Laura High, Luke Jones, Peter J. Houghton, Jean-Pierre Bourquin, Elise Tonna, Malcolm A. Smith, Chintanu Sarmah, Viktoras Frismantas, Catherine A. Billups, Richard B. Lock, Kathryn Evans, Beat Bornhauser, Anthony Letai
Purpose: Predictive biomarkers are required to identify patients who may benefit from the use of BH3 mimetics such as ABT-263. This study investigated the efficacy of ABT-263 against a panel of patient-derived pediatric acute lymphoblastic leukemia (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::597045feea2bc0969a2fcd09c3651026
https://www.zora.uzh.ch/id/eprint/101257/
https://www.zora.uzh.ch/id/eprint/101257/
Autor:
William R. Wilson, Richard B. Lock, Jennifer Richmond, Peter J. Houghton, Donya Moradi Manesh, Kathryn Evans, Malcolm A. Smith, Stephen M. F. Jamieson, Hernan Carol
Publikováno v:
Cancer Research. 73:2745-2745
Despite the success of current therapies for childhood acute lymphoblastic leukemia (ALL), novel treatments are required to treat high-risk or relapsed patients. PR-104 is a pre-prodrug hydrolyzed in vivo to PR-104A, which is then metabolized under h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e96e689f3303d7e77e72251cadfefaa9
https://doi.org/10.1158/1538-7445.am2013-2745
https://doi.org/10.1158/1538-7445.am2013-2745